CYP1A2 and dry eye syndrome: As expected, VRCZ treatment induced translocation of AhR to nucleus and upregulate AhR target genes, CYP1A1, CYP1A2 and CYP1B1 in KCs, indicating that VRCZ serves as AhR activator.